- In November 2024, Bavarian Nordic, a Danish biotech company, secured orders worth approximately USD 340 million for its mpox and smallpox vaccines for 2025, reflecting strong demand in Europe
- In September 2024, Molex announced that Phillips Medisize, which was acquired by Molex in 2016, entered into an agreement to acquire Vectura Group Limited, a UK-based contract development and manufacturing organization. Vectura specializes in inhalation drug device design, formulation, and development for various drug delivery methods, thereby expanding Phillips Medisize's pharmaceutical sector capabilities
- In January 2024, Kindeva Drug Delivery acquired Summit Biosciences Inc., a contract development and manufacturing organization (CDMO) focused on intranasal drug delivery. This acquisition introduces a new drug-delivery platform, enhancing Kindeva's ability to develop a broader range of complex drug-device combination products
- In December 2022, Vaxxas completed a significant financing round, raising USD 23 million to support the development of needle-free vaccination technology, highlighting the industry's ongoing focus on innovative vaccine administration solutions
- In January 2022, Pfizer and Acuitas Therapeutics entered into a partnership agreement for a lipid nanoparticle delivery system for mRNA vaccines and therapeutics
